Synonym
MK25; MK-25; MK 25; MK2 Inhibitor IV; MK2 Inhibitor-IV; MK2-IN-1
IUPAC/Chemical Name
5-(4-Chlorophenyl)-N-[4-(1-piperazinyl)phenyl]-N-(2-pyridinylmethyl)-2-furancarboxamide monohydrochloride
InChi Key
AZDOSXSDARWKGX-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H25ClN4O2.ClH/c28-21-6-4-20(5-7-21)25-12-13-26(34-25)27(33)32(19-22-3-1-2-14-30-22)24-10-8-23(9-11-24)31-17-15-29-16-18-31;/h1-14,29H,15-19H2;1H
SMILES Code
O=C(C1=CC=C(C2=CC=C(Cl)C=C2)O1)N(C3=CC=C(N4CCNCC4)C=C3)CC5=NC=CC=C5.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
MK2-IN-1 hydrochloride is a potent and selecitve MAPKAPK2(MK2) inhibitor(IC50=0.11 uM) with a non-ATP competitive binding mode.
In vitro activity:
Through this effort, the initial gap observed between in vitro binding activity and cellular activity in the lead identification stage was very much reduced. Compound 28 (MK25) was identified with single digit binding activity (IC(50)=8 nM) and good cellular activity (EC(50)=310 nM). This provides further evidence that non-ATP-competitive binding MK2 inhibitors are feasible by targeting the outside ATP pocket.
Reference: Bioorg Med Chem Lett. 2012 Jan 1;22(1):65-70. https://pubmed.ncbi.nlm.nih.gov/22169260/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMF |
30.0 |
58.89 |
|
| DMSO |
65.0 |
127.59 |
|
| DMSO:PBS (pH 7.2) (1:1) |
0.5 |
0.98 |
|
| Ethanol |
50.5 |
99.13 |
|
| Water |
51.0 |
100.11 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
509.43
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
Huang X, Zhu X, Chen X, Zhou W, Xiao D, Degrado S, Aslanian R, Fossetta J, Lundell D, Tian F, Trivedi P, Palani A. A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors. Bioorg Med Chem Lett. 2012 Jan 1;22(1):65-70. doi: 10.1016/j.bmcl.2011.11.074. Epub 2011 Nov 23. PMID: 22169260.
In vitro protocol:
Huang X, Zhu X, Chen X, Zhou W, Xiao D, Degrado S, Aslanian R, Fossetta J, Lundell D, Tian F, Trivedi P, Palani A. A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors. Bioorg Med Chem Lett. 2012 Jan 1;22(1):65-70. doi: 10.1016/j.bmcl.2011.11.074. Epub 2011 Nov 23. PMID: 22169260.
1: Li XE, Lopetcharat K, Drake MA. Parents' and children's acceptance of skim chocolate milks sweetened by monk fruit and stevia leaf extracts. J Food Sci. 2015 May;80(5):S1083-92. doi: 10.1111/1750-3841.12835. Epub 2015 Apr 6. PubMed PMID: 25847181.
2: Ahmad M, Zahir ZA, Asghar HN, Asghar M. Inducing salt tolerance in mung bean through coinoculation with rhizobia and plant-growth-promoting rhizobacteria containing 1-aminocyclopropane-1-carboxylate deaminase. Can J Microbiol. 2011 Jul;57(7):578-89. doi: 10.1139/W11-044. Epub 2011 Jul 19. PubMed PMID: 21770816.
3: Adaikkalam V, Swarup S. Characterization of copABCD operon from a copper-sensitive Pseudomonas putida strain. Can J Microbiol. 2005 Mar;51(3):209-16. PubMed PMID: 15920618.
4: Syn CK, Magnuson JK, Kingsley MT, Swarup S. Characterization of Pseudomonas putida genes responsive to nutrient limitation. Microbiology. 2004 Jun;150(Pt 6):1661-9. PubMed PMID: 15184552.
5: Adaikkalam V, Swarup S. Molecular characterization of an operon, cueAR, encoding a putative P1-type ATPase and a MerR-type regulatory protein involved in copper homeostasis in Pseudomonas putida. Microbiology. 2002 Sep;148(Pt 9):2857-67. PubMed PMID: 12213931.
6: Tatarov G. [Developing an avirulent mutant of Aujeszky's disease virus using the effect of 5 bromodesoxyuridine]. Tijdschr Diergeneeskd. 1983 Mar 1;108(5):204-9. Dutch. PubMed PMID: 6302945.
7: Naneva G, Vasileva I, Motovski A, Gergov P. [Stability of Aujezky's disease virus strain MK25 in an aerosol]. Vet Med Nauki. 1983;20(9):25-9. Bulgarian. PubMed PMID: 6320523.
8: Ivanov IE, Arsov R, Sizov I, Terziev S. [Evaluation of the specificity of skin allergy tests in cattle with IBR-IPV]. Vet Med Nauki. 1983;20(1):30-5. Bulgarian. PubMed PMID: 6306906.
9: Truijen WT, Tielen MJ, Brus DH, van Exsel AC. [Aujeszky's disease: maternal immunity of piglets born of sows inoculated with various vaccines (author's transl)]. Tijdschr Diergeneeskd. 1981 Aug 1;106(15):756-66. Dutch. PubMed PMID: 6269251.
10: Tielen MJ, van Exsel AC, Brus DH, Truijen WT. [Aujeszky's disease: serological responsiveness after vaccination of 6-10-week-old piglets with maternal antibody (author's transl)]. Tijdschr Diergeneeskd. 1981 Aug 1;106(15):739-47. Dutch. PubMed PMID: 6269250.
